[HSIC] Henry Schein Thesis 2026: Post-Ransomware Recovery Tests Dental Distribution Resilience
Key Takeaways
- October 2024 Ransomware Cyberattack Recovery: October 14-15, 2024 BlackCat/ALPHV ransomware cyberattack disrupted Henry Schein's distribution operations for ~3-4 weeks; selected ~$300M+ FY2024-2025 revenue impact + $50-100M response costs; selected post-2024 distribution operations restoration + selected customer order backlog clearance; FY2026 catalyst: continued recovery + selected revenue normalization toward $14-15B (+5-8%).
- Dental Distribution Leadership: Dental segment ~$8B FY2025 (~60% of total; +3-5% YoY); selected ~250K+ dental customers globally (~25-30% global dental distribution market share); selected Henry Schein Practice Solutions (~10K+ dental practices on practice management software); selected post-2024 dental procedure normalization; FY2026 expected Dental toward $8.4-8.8B (+5-8%) on continued recovery + selected practice management software acceleration.
- Medical Cycle Stabilization: Medical segment ~$4B FY2025 (~30% of total; +5-8% YoY); selected physician office + alternate care medical supplies; selected post-2024 vaccine + medical procedure normalization; selected ~150K+ medical customers; FY2026 expected Medical toward $4.2-4.5B (+5-10%).
- Long-Tenured CEO + Capital Return: CEO Stanley Bergman since 1989 (~36-year tenure; selected one of longest-tenured S&P 500 CEOs; CPA + Wits University South Africa); selected modest dividends + buybacks; investment-grade Baa2/BBB credit ratings; FCF $400-600M; FY2026 expected continued buyback discipline.
Company Background
Henry Schein, Inc. (NASDAQ: HSIC) is the leading global dental + medical distribution + dental practice management software firm. Founded 1932 by Henry Schein in Queens New York as small dental supply company; selected ~93-year heritage; selected post-1995 IPO continued aggressive distribution roll-up + selected international expansion across ~32+ countries. The company conducted IPO November 1995 NASDAQ; selected post-IPO ~30x+ stock appreciation through 2024 albeit with selected post-October 2024 cyberattack volatility.
The company operates three reporting segments: Dental ~60% of revenue ($8B — selected dental supplies + equipment + selected practice management software including Dentrix + Easy Dental + selected; selected ~250K+ dental customers globally including selected ~25-30% global dental distribution market share), Medical ~30% ($4B — selected physician office + alternate care medical supplies + selected ~150K+ medical customers including selected primary care + urgent care + ambulatory surgery centers), and Technology + Value-Added Services ~10% ($1.3B — selected practice management software + selected revenue cycle management + selected dental laboratory).
Headquartered in Melville New York; ~25,000+ employees globally with FY2025 revenue ~$13-14B (+5-7% YoY) generating ~$500-700M net income (~4-5% net margin reflecting selected distribution low-margin model + selected post-cyberattack operating expense impact) and ~$4.20-5.20 EPS on ~125M diluted shares.
CEO Stanley Bergman since 1989 (~36-year tenure; selected one of longest-tenured S&P 500 CEOs; CPA + Wits University South Africa Bachelor of Commerce; selected concurrent Chairman + CEO; selected ~40-year company career joining Henry Schein 1980). Selected Bergman era characterized by: (i) selected ~$300M FY1990 → ~$13B+ FY2025 revenue scale (~40x growth); (ii) selected aggressive distribution + selected technology M&A; (iii) selected dental + medical + technology vertical integration; (iv) selected international expansion to ~32+ countries.
October 2024 Ransomware Cyberattack: $300M+ Revenue Impact
October 14-15, 2024 BlackCat/ALPHV ransomware cyberattack on Henry Schein's distribution operations represented selected most significant operational disruption in company history. Selected attack details: (i) selected BlackCat/ALPHV ransomware group breach (selected Russia-affiliated cybercriminal group also responsible for selected MGM + UnitedHealth Change Healthcare attacks); (ii) selected distribution operations disruption ~3-4 weeks (selected order processing + selected ERP systems + selected); (iii) selected ~$300M+ FY2024-2025 revenue impact (selected primarily Q4 2024 + Q1 2025); (iv) selected $50-100M response costs (selected forensic investigation + selected ransom decision + selected system rebuild + selected legal/regulatory).
Selected company response: (i) selected refused ransom payment; (ii) selected engaged Mandiant + selected forensic firms; (iii) selected ~$50-100M cybersecurity infrastructure rebuild; (iv) selected enhanced cyber resilience post-2024; (v) selected continued customer service maintenance through manual order processing during outage. FY2025 expected revenue $13-14B reflecting selected post-cyberattack recovery + selected order backlog clearance. FY2026 catalyst: continued recovery + revenue normalization toward $14-15B (+5-8%).
Material change rule: secondary ransomware attack OR major customer attrition >5% post-2024 cyberattack OR major regulatory action affecting cyber liability OR major Henry Schein Practice Solutions software disruption.
Dental Distribution Leadership: $8B Trajectory + Practice Management Software
Dental segment revenue $8B FY2025 ($1.5B+; selected dental chairs + selected); (iii) selected practice management software via Henry Schein Practice Solutions Dentrix + Easy Dental (~$500M+ revenue; selected ~10K+ dental practices); (iv) selected ~250K+ dental customers globally (~25-30% global dental distribution market share); (v) selected post-2024 dental procedure normalization; (vi) selected Patterson Companies + selected Schein Pharmaceutical Services competitive intensity.60% of total; +3-5% YoY) reflects: (i) selected dental supplies ($5B+ revenue; selected dental consumables + equipment + selected); (ii) selected dental equipment (
FY2026 expected Dental toward $8.4-8.8B (+5-8%) reflecting: (i) continued post-2024 cyberattack recovery; (ii) selected dental procedure cycle stabilization; (iii) selected practice management software acceleration; (iv) selected international expansion.
Medical + Technology Diversification
Medical segment ~$4B FY2025 (30% of total; +5-8% YoY) reflects: (i) selected physician office medical supplies ($3B+ revenue); (ii) selected alternate care + ambulatory surgery centers; (iii) selected vaccine distribution (selected post-2024 normalization); (iv) selected ~150K+ medical customers. Technology + Value-Added Services ~$1.3B (~10%) selected practice management + selected revenue cycle + selected dental laboratory.
Key Core Metrics
| Metric | FY2022 | FY2023 | FY2024 | FY2025E | FY2026E |
|---|---|---|---|---|---|
| Total Revenue | $12.65B | $12.34B | $12.66B | $13-14B | $14-15B |
| Dental | $7.7B | $7.5B | $7.7B | $8B | $8.4-8.8B |
| Medical | $4.0B | $3.8B | $3.8B | $4B | $4.2-4.5B |
| Technology + VAS | $1.0B | $1.1B | $1.2B | $1.3B | $1.3-1.4B |
| Adj. Operating Margin | 6% | 6% | 5% | 4-5% | 5-6% |
| Adj. EPS | $5.16 | $4.90 | $4.50 | $4.20-5.20 | $5.00-6.00 |
| FCF | $500M | $480M | $300M | $400-600M | $500-700M |
| Capital Return | FY2024 | FY2025E | FY2026E |
|---|---|---|---|
| Dividend per Share | $0 | $0 | $0 |
| Buybacks | $300M | $200-400M | $300-500M |
| Total Capital Return | $300M | $200-400M | $300-500M |
| Credit Rating | Baa2/BBB | Baa2/BBB | Baa2/BBB |
Market Evaluation
HSIC currently trades at ~14-17x earnings reflecting: (i) selected post-October 2024 cyberattack overhang; (ii) selected category-leading dental distribution franchise; (iii) selected ~36-year long-tenured CEO Bergman leadership; offset by (iv) selected post-cyberattack operational + reputational risks; (v) selected dental + medical distribution low-margin model.
Selected peer comparison: Patterson Companies (PDCO ~10-13x P/E dental + animal health distribution), McKesson (MCK ~14-17x P/E pharmaceutical distribution), Cardinal Health (CAH ~14-17x P/E pharmaceutical distribution), Cencora (COR ~14-17x P/E pharmaceutical distribution). HSIC valuation reflects mid-tier distribution positioning post-cyberattack recovery.
FY2026 catalysts: (i) post-cyberattack revenue recovery; (ii) Dental cycle stabilization; (iii) Medical growth; (iv) Practice management software acceleration. Risks: (i) secondary ransomware attack; (ii) major customer attrition; (iii) Patterson + selected competitive intensity; (iv) major dental cycle reversal.
Post-Ransomware Recovery and Distribution Resilience
The FY2026 thesis hinges on Henry Schein's ability to complete post-October 2024 cyberattack recovery + sustain Dental distribution leadership + capitalize on Medical cycle stabilization. Revenue trajectory toward $14-15B FY2026 (+5-8%) signals selected continued recovery + selected revenue normalization + selected international expansion.
Adj. EPS $5.00-6.00 FY2026 (+15-20%) reflects selected operational leverage + post-cyberattack recovery + buyback compounding. Capital return at $300-500M FY2026 reflecting selected continued buyback discipline.
Material risks: (i) secondary ransomware attack; (ii) major customer attrition >5%; (iii) Patterson + selected dental distribution competitive intensity severe; (iv) major regulatory action.
FY2026-2027 base case: revenue $14-15B (+5-8%) + $14.5-15.5B (+3-5%); adj. EPS $5.00-6.00 + $5.50-6.50 (+10-15% growth); Dental $8.4-8.8B + $8.7-9.2B; Medical $4.2-4.5B + $4.4-4.8B; capital return $300-500M + $400-600M. Selected category-leading dental + medical distribution franchise + selected ~36-year CEO continuity + selected post-cyberattack recovery support continued strategic positioning through FY2027.